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1. Introduction
The most investigated thrombophilia related to obstetrical complications is the antiphospho‐
lipid antibodies syndrome (APS), also known as Hughes’ syndrome. APS is characterized by
recurrent thrombosis (arterial or venous, or both) and/or morbidity during pregnancy (losses
during early and late pregnancy and pre-eclampsia) associated with moderate to high plasma
levels of antiphospholipid (aPL) antibodies (anticardiolipin antibodies, antibodies to β2
glycoprotein I [β2GPI] or lupus anticoagulants) [1-2].
According to the last International consensus statement for APS diagnostic criteria, in order
to make diagnosis of the syndrome, the combination of at least one clinical and one laboratory
criterion is required [2] (Table 1).
Since aPL antibodies have thrombogenic properties, intraplacental thrombosis with maternal–
fetal blood exchange impairment was traditionally suggested to be the main pathogenic
mechanism responsible of fetal loss in patients with APS, providing the rationale for the use
of aspirin or heparin to prevent adverse pregnancy outcomes in APS [3-5].
Although the management of aPL antibodies-positive pregnant patients is controversial due to
the limited well-designed controlled trials, the current recommendation is to use low-dose
aspirin and prophylactic or therapeutic doses of heparin for patients fulfilling the updated
Sapporo APS classification criteria [2] and no treatment for asymptomatic (no history of
pregnancy complications and/or thrombosis) persistently aPL antibodies-positive patients [6].
© 2013 Tersigni et al.; licensee InTech. This is an open access article distributed under the terms of the
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In the last years, progress has been made in characterizing the molecular basis of aPL anti‐
bodies pathogenicity, which includes direct effects on platelets, endothelial cells and mono‐
cytes as well as activation of complement. Furthermore, it has been widely shown that
pregnancy loss cannot be attributed exclusively to placental thrombosis and that other
pathogenic mechanisms like functional trophoblast impairment, angiogenesis inhibition or
complement-mediated placental injury may occur (see more below). Based on these findings,
novel therapeutic targets are currently being explored for APS in order to address the unmet
needs of better, safer and ideally targeted therapy.
This chapter points to resume the known mechanisms of aPL antibodies-mediated pregnancy
impairment, the proven therapies and the new therapeutic perspectives to ameliorate obstetric
outcomes of pregnant women with APS.
2. Adverse pregnancy outcomes associated to APS
Beyond thromboses, obstetric complications are the other main features of APS. Such associ‐
ation is supported by several epidemiological studies and experimental models showing that
passive transfer of aPL IgG induces fetal losses and growth retardation in pregnant naive mice,
giving the proof that aPL antibodies are involved in determining the clinical manifestations of
the syndrome [7-9]. The most common adverse pregnancy outcome associated to APS is
Clinical criteria Laboratory criteria
Vascular thrombosis
• One or more clinical episodes of arterial, venous, or small vessel thrombosis,
in any tissue or organ.
• Thrombosis should be supported by objective validated criteria—ie,
unequivocal findings of appropriate imaging studies or histopathology. For
histopathological support, thrombosis should be present without substantial
evidence of inflammation in the vessel wall.
Pregnancy morbidity, defined by one of the following criteria:
• One or more unexplained deaths of a morphologically healthy foetus at or
beyond the 10th week of gestation, with healthy foetal morphology
documented by ultrasound or by direct examination of the fetus.
• One or more premature births of a morphologically healthy newborn baby
before the 34th week of gestation because of: eclampsia or severe
preeclampsia defined according to standard definitions or recognized features
of placental failure.
• Three or more unexplained consecutive spontaneous abortions before the
10th week of gestation, with maternal anatomical or hormonal abnormalities
and paternal and maternal chromosomal causes excluded. In studies of
populations of patients who have more than one type of pregnancy morbidity,
investigators are strongly encouraged to stratify groups of patients according
to one of the three criteria.
• Lupus anticoagulant present in plasma, on
two or more occasions at least 12 weeks
apart, detected according to the guidelines
of the International Society on Thrombosis
and Hemostasis (Scientific Subcommittee on
lupus anticoagulant/ phospholipid-
dependent antibodies).
• Anticardiolipin antibody of IgG or IgM
isotype, or both, in serum or plasma, present
in medium or high titres (ie, "/>40 GPL or
MPL, or greater than the 99th percentile) on
two or more occasions, at least 12 weeks
apart, measured by a standardized ELISA.
• Anti-β2-gycoprotein 1 antibody of IgG or
IgM isotype, or both, in serum or plasma (in
titres greater than the 99th percentile),
present on two or more occasions, at least
12 weeks apart, measured by a standardized
ELISA, according to recommended
procedures.
Table 1. Revised diagnostic criteria of APS [2].
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recurrent miscarriage, defined as the occurrence of three or more unexplained consecutive
miscarriages before the 10th week of gestation. Other obstetric features of APS are unexplained
fetal deaths, occurring at or beyond the 10th week of gestation, and premature births of a
morphologically healthy newborn baby before the 34th week of gestation because of eclampsia
or severe preeclampsia [10].
Recurrent miscarriage occurs in about 1% of the general population attempting to have children
[11] and about 10–15% of women with recurrent miscarriage are diagnosed with APS [12,13].
Fetal death in the second or third trimesters of pregnancy occurs in up to 5% of unselected
pregnancies [14] but it is less likely as pregnancy advances [15]. Although fetal death occurs
significantly most often in APS [16], the overall contribution of this syndrome to its pathogene‐
sis is unknown, because of the effect of other possible contributing factors such as underlying
hypertension or pre-existing comorbidities, like systemic lupus erythematosus (SLE) or renal
diseases. Furthermore, it has been observed that pregnant women with diagnosis of APS are at
increased risk for developing preeclampsia or placental insufficiency.
Even  if  it  is  still  unknown  the  precise  relationship  between  aPL  antibodies  and  the
occurrence of obstetric complications, aPL antibodies seem to be detectable in 11–29% of
women with preeclampsia, compared with 7% or less in controls and in 25% of women
delivering  growth  restricted  fetuses  [17].  Furthermore,  results  from  prospective  cohort
studies indicate that among pregnant women with high concentrations of aPL antibodies,
10–50% develop preeclampsia, and more than 10% of these women deliver infants who are
small for gestational age [17].
A significant correlation between aPL positivity and increased risk of fetal  loss has also
been  established.  In  particular,  the  strongest  association  has  been  observed  with  ACA
positivity, followed by annexin V, lupus anticoagulant and anti-β2GPI. In addition, lupus
anticoagulant seems to be significantly associated with early pregnancy loss compared to
late pregnancy loss [18]
3. Pathogenetic mechanisms mediated by aPL antibodies and related
therapeutic approaches
3.1. Vascular and placental thrombosis
The molecular mechanisms underlying thrombosis and fetal death in APS have long been
investigated. The main target antigens reported in patients with APS include β2GPI/cardioli‐
pin, prothrombin and annexin V [19]. Other putative antigens are thrombin, protein C, protein
S, thrombomodulin, tissue plasminogen activator, kininogens (high or low molecular),
prekallikrein, factor VII/VIIa, factor XI, factor XII, complement component C4, heparan sulfate
proteoglycan, heparin, oxidised low-density lipoproteins [19,20]. The main autoantigens are
attracted to negatively charged phospholipids exposed on the outer side of cell membranes in
great amounts only under special circumstances such as damage or apoptosis (e.g. endothelial
cell) or after activation (e.g. platelets) [19].
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Endothelial cells, activated by aPL antibodies with anti-β2GPI activity, express adhesion
molecules such as intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, E-
selectin, and both endothelial cells and monocytes upregulate the production of tissue factor
(TF) [21]. All at once, activated platelets increase expression of glycoprotein IIb-IIIa and
synthesis of thromboxane A2, determining a procoagulant state [21-25].
Additional mechanisms promoting clot formation could be represented by interaction of aPL
antibodies with proteins implicated in clotting regulation, such as annexin A5, prothrombin,
factor X, protein C and plasmin [20,21,26].
Recent results from studies in mice highlight the role of inflammation in the pathogenesis of
APS, showing a central role for complement activation in determining thrombosis and fetal
loss induced by aPL antibodies [27,28]. Because many individuals with high aPL antibodies
titers remain asymptomatic, a “second hit” hypothesis has been proposed. It is likely that in
the aPL antibodies-induced vascular procoagulant state, activation of the complement cascade
might close the loop and provoke thrombosis, often in the presence of a second hit, like tobacco,
inflammation, or oestrogens [26,29,30].
Starting from the observation of the intravascular aPL antibodies-mediate clot formation,
initially, intraplacental thrombosis was considered the main pathogenic mechanism media‐
ting fetal loss in APS. This hypothesis of placental damage was supported by the finding of
thrombosis and infarction in placentas from women with APS and by the demonstration of aPL
antibodies capability to induce a procoagulant state in vitro through several mechanisms,
including their ability (specifically, anti-β2GPI antibodies) to disrupt the anticoagulant annexin
A5 shield on trophoblast and endothelial cell monolayers [20,31,32]. Supporting the in vitro
findings, a significantly lower distribution of annexin A5 covering the intervillous surfaces was
found in the placentas of aPL antibodies-positive women in comparison with normal controls
[33]. These observations supported the introduction of heparin in the prevention of fetal loss in
APS, preferred to oral anticoagulant therapies for its safer profile for the fetus. Indeed, it was
demonstrated that heparin, at concentrations that are reached therapeutically in vivo, greatly
enhanced the plasmin-mediated cleavage of β2-GPI. Considering that the cleaved forms of β2-
GPI cannot bind to PL and may be cleared more rapidly from the circulation than native β2-
GPI [34], interaction with heparin should greatly reduce the prothrombotic effects of anti-β2-
GPI antibodies. Yet, some clinical trials confirmed heparin therapy effectiveness in improving
pregnancy outcomes in APS patients [35].
Nevertheless, since recurrence of thrombotic events occurs despite the therapy and thrombosis
cannot account for all of the histopathologic findings in placentae from women with APS, other
mechanisms of reproductive impairment were supposed to be involved [36,37].
3.2. Defective placentation
3.2.1. Trophoblast invasiveness impairment
New aPL antibodies-mediated pathogenic mechanisms have been proposed during the last
fifteen years: anti-β2GPI antibodies seem to bind directly the maternal decidua and the
invading trophoblast, determining defective placentation.
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On the fetal side, β2GPI has been shown to be expressed on trophoblast cell membranes,
explaining the placental tropism of anti-β2GPI antibodies. Being a cationic plasma protein,
β2GPI has been suggested to bind to exposed phosphatidylserine on the external cell mem‐
branes of trophoblasts undergoing syncitium formation [38].
β2GPI-dependent antibodies can adhere to human trophoblast cells in vitro [39], consistently
with the hypothesis that the visibility of anionic PLs on the external cell surface during
intertrophoblastic fusion might offer a useful substrate for the cation PL-binding site [40,41].
The binding to anionic structures induces the expression of new cryptic epitopes and/or
increases the antigenic density, two events that are apparently pivotal for the antibody binding
[42]. In vitro studies with both murine and human monoclonal antibodies, as well as with
polyclonal IgG antibodies from APS patients, have clearly demonstrated a binding to troph‐
oblast monolayers [39,43]. Interestingly, antibodies obtained from patients with APS, once
bound, can affect the trophoblast functions in vitro, inducing cell injury and apoptosis,
inhibition of proliferation and formation of syncitia, decreased production of human chorionic
gonadotrophin, defective secretion of growth factors and impaired invasiveness [39]. β2GPI-
dependent aPL antibodies seem, therefore, to represent the main pathogenic autoantibodies
in obstetrical APS.
The most important mechanism by which heparin acts protecting placenta in APS seems to be
its ability to prevent the binding of aPL antibodies to trophoblast cells. Indeed, using an
expression/site-directed mutagenesis approach, Guerin demonstrated that the primary
heparin-binding site of β2-GPI is the positively charged site located within the fifth domain of
the protein, which also binds to PL [44]. Furthermore, we demonstrated that heparin reduces
the aPL antibody binding to trophoblast cells in vitro and that it is able to restore placental
invasiveness and differentiation [45,46].
Recent findings have underlined a further mechanism by which aPL antibodies binding to
human trophoblast could affect its functions: the aPL antibodies-mediated reduction of
placental Heparin-Binding Epidermal Growth Factor–like growth factor (HB-EGF) expression.
HB-EGF is a member of the EGF family [47,48]. It has been shown to induce an invasive
trophoblast phenotype in human and mouse blastocysts [49,50] and to initiate the molecular
and cellular changes characteristic of decidualization in mice [51]. HB-EGF is expressed in the
human placenta during the first trimester, primarily within the villous trophoblast, but also
in the extravillous cytotrophoblast, predominantly at the sites of cytotrophoblast extravillous
invasion [52]. Women with preeclampsia and infants small for gestational age display
decreased placental expression of HB-EGF [53], strongly suggesting an association between
HB-EGF down-regulation, poor trophoblast invasion, and failed physiologic transformation
of the spiral arteries occurring in these disorders.
Interestingly, also in placental tissues obtained from women with APS, we found reduced
expression of HB-EGF [54]. Furthermore, we showed that polyclonal and monoclonal aPL
antibodies bind trophoblast monolayers in vitro significantly reducing the synthesis and the
secretion of HB-EGF [55]. The ability of exogenous recombinant HB-EGF to reduce the aPL
antibodies mediated effects on trophoblast cells supports the hypothesis of a key pathogenic
role of this molecule in mediating APS-related adverse pregnancy outcomes.
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We also observed that the addition of heparin inhibited aPL antibodies binding and restored
HB-EGF expression in a dose-dependent manner [54]. These findings suggest that the reduc‐
tion of aPL antibodies-mediated HB-EGF represents an additional mechanism that is respon‐
sible for the defective placentation associated with APS and provide one more proof that
heparin works in protecting pregnancy from aPL antibodies-induced damage by inhibiting
antibody binding to trophoblast cells.
3.2.2. Endometrial angiogenesis inhibition
On the maternal side, endometrial endothelial angiogenesis inhibition has been suggested to
be a further aPL antibodies-mediated mechanism of placental damage. Indeed, aPL antibodies
have been observed to selectively bind in vitro to endothelial cells isolated from human
endometrium (HEEC) and to inhibit endothelial cell differentiation into capillary-like tubular
structures, by reducing matrix metalloproteinase-2 (MMP-2) activity and vascular endothelial
growth factor (VEGF) secretion, via a suppression of intracellular NFKB DNA binding activity
[55]. Such an aPL antibodies-mediated inhibition of angiogenesis has also been confirmed in
vivo in a murine model, showing a reduced angiogenesis in subcutaneous implanted angior‐
eactors in aPL antibodies-inoculated mice [55]. Since it is well known that endometrial
angiogenesis and decidualization are fundamental prerequisites for successful implantation
and placental development, aPL antibodies-inhibition of this central process provides an
important additional mechanism able to explain the association between APS and pregnancy
complications associated to placental failure, like miscarriage, fetal growth restriction and
preeclampsia.
Recently, we investigated whether two low molecular weight heparins (LMWHs), tinzaparin
and enoxaparin, have an effect on the aPL antibodies-inhibited endometrial angiogenesis. We
demonstrated that the addition of the two LMWHs prevents aPL antibodies-mediated
inhibition of HEEC angiogenesis, both in vitro and in vivo in a murine model, and that LMWHs
are able to restore Nuclear Factor-κB (NF-κB) and/or STAT-3 activity, VEGF secretion and
MMP-2 activity inhibited by aPL antibodies [56]. A noteworthy aspect of our results was that
tinzaparin improved aPL-inhibited in vitro angiogenesis and STAT-3 activity more effectively
than enoxaparin but it is difficult to explain this difference between the two LMWHs and
caution is necessary in extrapolating the obtained results.
In conclusion, this study provides the demonstration of a beneficial effect of LMWHs on the
aPL antibodies-inhibited HEEC angiogenesis offering a new mechanism whereby treatment
with heparin protects early pregnancy in APS.
Beyond heparin administration, recently, a new therapeutic perspective has been investigated
to provide a safer profile therapy to prevent aPL antibodies-mediated angiogenesis inhibition.
During the last decade, several groups attempted to neutralize the pathogenic effect of aPL
antibodies by using synthetic peptides reproducing the β2GPI epitopes recognized by these
antibodies [57,58].
An alternative approach by other groups employed synthetic portions of the whole molecule
able to compete with β2GPI in its binding to the natural cell targets, ultimately inhibiting its
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expression and the recognition by specific autoantibodies [59,60]. It has been shown that a
twenty amino acid synthetic peptide of viral origin spanning Thr101-Thr120 of ULB0-HCMVA
from human Cytomegalovirus (TIFI) shares similarity with a 15 amino acid sequence rich in
lysines in the Vth domain of β2GPI located in the PL-binding site [61]. TIFI inhibits the binding
of FITC-conjugated β2GPI to human endothelial cells and murine monocytes in vitro. It has
been demonstrated that this peptide is not recognized by aPL antibodies but it is able to reverse
the aPL antibodies-mediated thrombosis in mice [59]. Furthermore, TIFI was recently shown
to inhibit also the binding of monoclonal human β2GPI-dependent aPL antibodies to human
trophoblast in vitro, and, more importantly, it has been observed that repeated injections of
TIFI protected pregnant naïve mice from fetal loss and growth retardation induced by passive
infusion of human aPL IgG [62-64]. Since β2GPI was shown to bind endothelial cells and
trophoblasts through the PL-binding site, it has been suggested that TIFI might compete with
β2GPI in the binding to cell membranes so reducing the amount of the target antigen available
for aPL antibodies and ultimately might reverse the autoantibody-mediated pro-thrombotic
or fetal loss effects [59,61-65] (Figure 1).
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Figure 1. TIFI competes with β2GPI in the binding to HEEC membranes reducing the amount of the target antigen
available for aPL antibodies and ultimately reverses the autoantibody-mediated fetal loss [66].
Based on these recent discoveries, we examined the ability of TIFI to interfere with aPL
antibodies-mediated inhibition of human endometrial angiogenesis and we observed that the
peptide is able to revert the anti-angiogenic effects mediated by a β2GPI-dependent aPL
monoclonal IgG on HEEC both in vitro and in vivo [66]. We showed for the first time that TIFI
is able to prevent the effects of β2GPI-dependent aPL antibodies on human endometrial
endothelial cell (HEEC) functions. In fact, the addition of TIFI to HEEC cultures restores VEGF
expression and MMP-2 gelatinolytic capacity affected by β2GPI-dependent monoclonal aPL
antibodies [66]. This finding is also confirmed by parallel experiments performed in a murine
model of in vivo angiogenesis [66].
3.3. Inflammation
A physiological pregnancy development requires a fine regulation of the maternal immune
response during embryo implantation. Acute inflammatory events are recognized causes of
Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…
http://dx.doi.org/10.5772/56862
89
adverse pregnancy outcomes, and proinflammatory mediators, such as complement, tumor
necrosis factor (TNF), and CC chemokines, have been shown to play a role in animal models
of aPL antibodies-induced fetal loss [67].
Recently, the excessive activation of complement system at the fetal-maternal interface has
been proposed as an additional aPL antibodies-mediated mechanism of placental damage
responsible for negative outcome in APS. In pregnant murine model of APS, Girardi et al.
demonstrated that aPL antibodies, preferentially targeted at deciduas and placentas, activate
the complement system through the classical pathway, leading to generation of potent
anaphylatoxins and mediators of effector-cell activation. The recruitment of inflammatory cells
accelerates local alternative pathway activation and creates a proinflammatory amplification
loop that enhances complement component 3 (C3) activation and deposition, generates
additional C3a and C5a and results in further influx of inflammatory cells into the placenta [8].
The pathogenic mechanism of complement-mediated fetal loss induced by aPL antibodies is
also supported by the protection that deficiency in complement components confers on the
animals, or that follows from in vivo inhibition of complement [68,69]. Hence, the complement
system could be a potential therapeutic target in aPL-positive patients.
Interestingly, Girardi and co-workers demonstrated that treatment with heparin prevent
complement activation in vivo and protect mice from pregnancy complications induced by
aPL antibodies [28]. Such low doses of heparin, lacking anticoagulant effects, inhibited
inflammatory responses at the level of leukocyte adhesion and influx and limited tissue injury
[70-73] Neither fondaparinux nor hirudin, other anticoagulants without known effects on
complement [74], prevented pregnancy loss, demonstrating that anticoagulant therapy gives
insufficient protection against APS-associated miscarriage [28].
Moreover, it has been demonstrated that heparin possesses the ability to inhibit lipopolysac‐
charide-induced proinflammatory cytokines (tumour necrosis factor α, interleukin 6, 8 and
1β) [75], involved in recurrent fetal loss of a murine model of APS [76].
Administration of intravenous immunoglobulin (IVIG) has been proposed as a possible
treatment to prevent pregnancy loss in APS. IVIG may act by modulating the effect of cytokines
as well as by inhibiting the action of pathological antibodies by either the interaction of the Fc
portion of immunoglobulin with Fc receptors or the Fab receptors, or by passively acting as
anti-idiotypic. IVIG also modulates the activation and effector functions of B and T lympho‐
cytes, neutralizes pathogenic autoantibodies, and interferes with antigen presentation.
Furthermore, the anti-inflammatory effect of IVIG may be due to interaction with the com‐
plement system [77].
IVIG have been shown to reduce the number of fetal resorptions in mice in which APS had
been induced by immunization with aPL [78]. However, in a multicenter placebo controlled
pilot study, the administration to pregnant women with APS of IVIG associated to low-dose
aspirin plus heparin did not improve obstetric or neonatal outcomes beyond those achieved
with a heparin and low-dose aspirin regimen [79].
Recently, Blank and coworkers demonstrated that anti-anti- β2GPI specific IVIG (sIVIG) are
able to improve significantly the pregnancy outcome in BALB/c mice passively infused with
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anti-β2GPI antibodies. They also observed that incubation of sIVIG restored the anti-β2GPI
antibodies-inhibited invasiveness of both JAR cells and human trophoblast cells in vitro. Based
on these results, APS sIVIG may be considered as potential specific therapeutic safe compound
for developing a treatment for APS patient’s early fetal loss [80].
Much research is still needed on the effects and proper indications for IVIG in reproductive
failure. However, its prohibitive cost will probably prevent it ever becoming a first-line drug
and its place is probably best reserved for severely affected patients who cannot be helped by
simpler modes of treatment.
A new potential mechanism of aPL antibodies-mediated fetal loss linking TF and complement
activation has been recently proposed. TF, best known as the primary cellular initiator of blood
coagulation, also contributes to a variety of biological processes. In particular, TF is involved
in inflammation and cell injury processes by interacting with protease-activated receptors
(PARs) [81], a subfamily of related G protein-coupled receptors. Complexes of TF-FVIIa and
TF-FVIIa-factor Xa (FXa) as well as FXa and thrombin induce pro-inflammatory signals by
activating PARs and inducing the expression of TNF-α, interleukins, and adhesion molecules
[82–84].
Increased expression of TF on monocytes from patients with APS has been reported [85–87]
and in vitro studies support a direct role for aPL antibodies in inducing monocyte TF expres‐
sion. Indeed, incubation of normal monocytes with IgG from patients with APS or monoclonal
aPL antibodies has been shown to induce TF expression and activity in these cells [88–90]. In
particular, anti-β2GPI human monoclonal antibodies derived from APS patients enhance
monocyte TF mRNA and activity in a β2GPI-dependent fashion [91]. Similarly, aPL antibodies
(and specifically anti-β2GPI antibodies) have been shown to induce TF, along with inflamma‐
tory cytokines and adhesion molecules, on endothelial cells [92–94].
Ritis et al. reported that complement activation is a fundamental process in determining aPL-
induced increase of TF expression on neutrophils. Indeed, in this study the authors showed
that complement component C5a induced TF synthesis and expression on neutrophils through
interaction with C5a receptor [95].
Based on this finding, Redecha et al. investigated whether TF contributes to aPL antibodies-
induced fetal loss in mice and observed that mice treated with aPL antibodies showed strong
TF staining throughout  the  decidua and on embryonic  debris  [96].  Surprisingly,  neither
increase in fibrin staining nor thrombi was associated with increased TF staining in deciduas
from  aPL  antibodies-treated  mice  [96].  Moreover,  anticoagulation  with  hirudin  and
fondaparinux was not sufficient to prevent pregnancy loss in this model. Neither TF increase
nor  fetal  death was observed in  mice  deficient  in  complement  component  C5a receptor
(C5aR) treated with aPL antibodies,  demonstrating the importance of  C5a-C5aR interac‐
tion in TF expression and fetal death in this model of APS. To assess the importance of TF
in aPL antibodies-induced fetal injury, Redecha et al. inhibited TF with a monoclonal anti-
mTF antibody 1H1 [96]. TF blockade prevented fetal death in aPL antibodies-treated mice
also  diminishing  complement  component  C3  deposition  and  neutrophil  infiltration  in
deciduas [96].
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Furthermore, Redecha et al. investigated the intracellular pathway of TF complement-
mediated activation, observing a 5-fold increase in PAR-2 mRNA expression in neutrophils of
aPL antibodies-treated mice when compared to untreated mice or mice treated with control
antibodies [97] as well as an increased reactive oxygen species (ROS) production and phago‐
cytosis in neutrophils from aPL antibodies-treated mice. Interestingly, neutrophils from PAR-2
deficient (PAR-2−/−) mice displayed a dramatic reduction of neutrophil activation in aPL
antibodies-treated mice [97]. Also ROS production and phagocytosis were significantly
reduced in neutrophils from PAR-2−/−mice treated with aPL antibodies compared with aPL
antibodies-treated wild-type mice. Specific monoclonal antibody 10H10 that selectively blocks
TF-VIIa signaling through PAR-2, but not antibody 5G9 that only prevents TF procoagulant
activity, prevented oxidative burst and increased phagocytosis in mice treated with aPL
antibodies [97]. These results are in accordance with the previous observation that anticoagu‐
lation does not rescue pregnancies in APS [43]. In addition, neutrophils from TF δCT/δCT mice
that carry a mutation in the cytoplasmic domain involved in PAR-2 signaling did not show
increased oxidative stress and phagocytosis in response to aPL antibodies [97]. This data
reinforces the idea that TF-FVIIa signaling is required for neutrophil activation and fetal injury
in APS.
The possible application of statins in the prevention of aPL antibodies-related adverse
pregnancy outcomes arises from their ability to suppress TF expression in various cell types
[98]. Knowing that TF is a crucial mediator in aPL antibodies-induced pregnancy loss and that
statins diminish TF expression, Girardi et al. investigated whether statins could prevent
pregnancy loss in aPL antibodies-treated mice and demonstrated that simvastatin and
pravastatin prevented fetal loss by reducing TF and PAR-2 expression on neutrophils, thus
preventing neutrophil activation [99]. aPL antibodies-dependent increase in free radical-
mediated lipid peroxidation in decidual tissue was also ameliorated by treatment with statins
[99] (Figure 2). These results suggest that statins prevent aPL antibodies-induced neutrophil
activation, thus protecting trophoblasts from oxidative damage and rescuing the fetuses.
However, given that statins are not major teratogens [100,101] and considering the beneficial
effects of statins in animal studies, statins should be considered as a possible treatment for
women with aPL antibodies-induced pregnancy complications. Clinical trials are needed to
confirm the effectiveness of its application to humans.
Mulla et al. Investigated further mechanisms characterizing the inflammatory process
occurring in vitro in trophoblast cells after aPL antibodies binding. Indeed, they demonstrated
that anti-β2GPI antibodies trigger an inflammatory response in trophoblast, characterized by
increased secretion of IL-8, MCP-1, GRO-α and IL-1β, and that this occurs in a TLR-4/MyD88-
dependent manner [102]. At high concentrations, these antibodies also induce caspase-
mediated cell death. This was attenuated upon disabling of the MyD88 pathway, suggesting
that anti-β2GPI-induced inflammatory mediators compromise trophoblast survival by acting
in an autocrine/paracrine manner. Enhanced IL-8, GRO-α and IL-1β secretion also occurred
when trophoblast were incubated with antibodies from patients with APS. Heparin attenuated
the anti-β2GPI antibody-mediated cell death, and also the pro-inflammatory response, but
only at high concentrations [102]. These findings demonstrate that aPL antibodies triggers a
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placental inflammatory response via the TLR-4/MyD88 pathway, which in turn compromises
trophoblast survival. Thus, the TLR-4/MyD88 pathway may provide a new therapeutic target
to improve pregnancy outcome in APS.
4. Conclusions
Heparin, associated to low dose aspirin, is considered nowadays the gold standard for the
prevention of obstetric complications in pregnant women with APS. Yet, heparin therapy
administered at subanticoagulant doses has improved pregnancy outcomes in some trials of
APS patients [35]. Several studies have proposed different mechanisms of action able to explain
the beneficial effect of heparin in preventing adverse pregnancy outcomes associated to APS
(Table 2).
↓ aPL antibodies binding to trophoblast cells
↑ Cleavage of β2GPI
↓ Complement activation
↓ Trophoblast cells apoptosis
↑ Trophoblast cells invasiveness and differentiation
↑ HB-EGF expression
↑Endometrial angiogenesis
Table 2. Heparin mediated mechanisms of placental protection from aPL antibodies.
However, in women with APS and history of obstetric failures, pregnancy complications recur
in the 15% of cases despite the therapy.
In the last years new mechanisms of aPL-mediated pregnancy impairment, like inflammation
and angiogenesis inhibition, and more specific target therapies have being examined in order
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Figure 2. Statins prevent C5a-induced upregulation of TF and PAR2 expression, thereby inhibiting the release of reac‐
tive oxygen species and suppressing amplification of complement activation by factors released from neutrophils.
Modified from Girardi G. et al., Journal of Reproductive Immunology 2009 [99].
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to treat more selectively the aPL antibodies-induced placental damage and to ameliorate the
reproductive performance of women with APS. Studies on humans are required to verify the
safety profile and effectiveness of new therapies proposed.
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